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Background
The reviewers report that a combination of benzodiaze-
pines (BZD) with antidepressants work in favour for the
treatment of depression, because it decreases drop outs
of treatment and it increases short-term response up to
four weeks [1]. Early achievement of symptomatic remis-
sion is critical to the long-term success of treatment [2].
Materials and methods
Using a sample of 100 patients with MDD who have
been visited in Barcelona’s Sant Martí Sud outpatient
mental health center during the year 2008, sociodemo-
graphical (gender, age) and clinical data (toxic consume,
psychiatric background, use of BZD) are analysed with
SPSS 15.0 statistical package
Results
There is use of BZD in a 76% of the sample, with a pre-
dominancy of the female gender (72.4% vs 27.6%), a glo-
bal average age of 56.55 ± 12.4 years. In relation to
personal psychiatric background it can be observed in
47.4% the absence of these, followed by 39.5% in which
there is presence of previous depressive episodes. There
is a predominancy in the absence of toxic abuse (97.4%)
and the absence of previous hospitalisations (81%)
It can be observed the following distribution by fre-
quencies in the use of BZD: diazepam (25%), dipotassic
clorazepate (23,7%), clonazepam (14.5%) and alprazolam
(10.5%). The average dose was 10.2 mg/d for diazepam,
22.9 mg/d for dipotasic clorazepate, 2.7 mg/d for clona-
zepam and 1 mg/d for alprazolam.
Conclusions
The use of BZD in the DMM is large in our sample but
the potential benefits of adding a BZD to an antidepres-
sant must be balanced judiciously against possible harms
including development of dependence and accident pro-
neness, on the one hand, and against continued suffering
following no response and drop out, on the other.
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